Evaluation of the activity and safety of CS 21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial
Authors:
- 7 September 2013
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (9) , 1158-1164
Abstract
Background Topical or systemic antiviral drugs reduce the duration of genital herpes recurrences but may not always alleviate functional symptoms. Objectives To assess the efficacy and safety of oxygenated glycerol triesters‐based CS21 barrier genital gel® vs. topical aciclovir and placebo (vehicle) in resolving functional symptoms and in healing of genital herpes recurrences. Methods A prospective randomized controlled, investigator‐blinded trial of CS21 barrier genital gel® vs. topical aciclovir (reference treatment) and placebo (vehicle) was designed. The primary endpoint was the cumulative score of four herpes‐related functional symptoms (pain, burning, itching and tingling sensations). Secondary endpoints included objective skin changes (erythema, papules, vesicles, oedema, erosion/ulceration, crusts), time to heal, local tolerance and overall acceptability of the treatment as reported by a self‐administered questionnaire. Results Overall, 61 patients were included. CS 21 barrier genital gel® was significantly more efficient than topical aciclovir and vehicle for subjective symptoms and pain relief in genital herpes recurrences; additionally, time to heal was significantly shorter with CS 21 than with vehicle, whereas no significantly difference was observed between patients receiving topical aciclovir and vehicle. The treatments under investigation were well tolerated and the adverse events were comparable in the three treatment groups. Conclusion Overall, these results support the interest of using of CS 21 barrier genital gel® in symptomatic genital herpes recurrences. Accordingly, this product offers a valuable alternative in topical management of recurrent genital herpes.Keywords
Funding Information
- Laboratoires Carilene
This publication has 12 references indexed in Scilit:
- Evaluation of the efficacy and safety of a CS20® protective barrier gel containing OGT compared with topical aciclovir and placebo on functional and objective symptoms of labial herpes recurrences: a randomized clinical trialJournal of the European Academy of Dermatology and Venereology, 2011
- The Treatment of Herpes Simplex InfectionsAn Evidence-Based ReviewArchives of internal medicine (1960), 2008
- Genital herpesThe Lancet, 2007
- Review of antiviral therapy for herpes labialis, genital herpes and herpes zosterExpert Review of Anti-infective Therapy, 2003
- Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infectionAntimicrobial Agents and Chemotherapy, 1984
- Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpesAntiviral Research, 1983
- Topically Administered Acyclovir in the Treatment of Recurrent Herpes Simplex Genitalis: A Controlled TrialThe Journal of Infectious Diseases, 1983
- Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapyJournal of Antimicrobial Chemotherapy, 1983
- Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infectionsThe American Journal of Medicine, 1982
- A Trial of Topical Acyclovir in Genital Herpes Simplex Virus InfectionsNew England Journal of Medicine, 1982